Evidence map›Paper›PMID 7518834›Full record

ArticleThe Journal of clinical investigation1994

Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells.

K Muta, S B Krantz, M C Bondurant, A Wickrema

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 176 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. The treatment of chronic anemia in heart failure: a global approach.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Erythropoietin levels in endocrinopathies.Journal of endocrinological investigation · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

K MutaDepartment of Medicine, Department of Veterans Affairs Medical Center, Nashville, Tennessee 37232.
S B Krantz
M C Bondurant
A Wickrema
Vanderbilt University · US

Funding

ERYTHROPOIETIN &REGULATION OF ERYTHROPOIESISR01DK015555 · NIDDK · VANDERBILT UNIVERSITY · PI KRANTZ, SANFORD B · 1986 to 2003
$864k
POSTGRADUATE TRAINING PROGRAM IN HEMATOLOGYT32DK007186 · NIDDK · VANDERBILT UNIVERSITY · PI KRANTZ, SANFORD B · 1986 to 2001
$366k
NIDDK NIH HHS 2 T32-DK07186NIDDK NIH HHS DK-15555
6 · The paper itself

Abstract

Erythropoietin (EP), insulin-like growth factor I (IGF-I) and stem cell factor (SCF) each reduce apoptosis of human erythroid progenitor cells. To determine if these growth factors have additional roles in stimulating erythropoiesis, the proliferation, maturation, and survival of highly purified human erythroid colony-forming cells (ECFCs) were studied during the application of different combinations of these growth factors in a serum-free liquid culture. EP maintained cell viability and supported heme synthesis during erythroid maturation, with little increase in viable cell number or stimulation of DNA synthesis. The addition of SCF with EP resulted in a substantial increase in DNA synthesis, which was greater than that seen with the addition of EP and was associated with a large expansion in the number of ECFCs. Thus EP, by itself, produces little increase in cell proliferation, and expansion of the number of erythroid cells depends upon the presence of SCF with EP. The addition of IGF-I with EP led to enhanced heme synthesis and moderate cellular proliferation, but also greatly enhanced nuclear condensation and enucleation in the late erythroblasts. Thus EP, by itself, is not sufficient for complete end-terminal nuclear condensation/enucleation and the presence of IGF-I is necessary for this complete process. While EP greatly reduced apoptosis during 16 h of incubation at 37 degrees C, the addition of SCF and IGF-I with EP had little additional effect, but these additions enhanced DNA synthesis > 3.4-fold. Thus SCF may have an additional role in directly stimulating proliferation through a process that is distinct from apoptosis. Our observations indicate that EP prevents apoptosis and maintains erythroid cell viability and development. IGF-I enhances erythroid maturation and proliferation, but the proliferation of erythroid progenitors is mainly controlled by the addition of SCF with EP, independent of an effect on apoptosis.

Indexed as

ApoptosisCells, CulturedDNAErythroid Precursor CellsErythropoietinHematopoietic Cell Growth FactorsHemeHumansInsulin-Like Growth Factor IRecombinant ProteinsStem Cell FactorDNAErythropoietinHematopoietic Cell Growth FactorsHemeInsulin-Like Growth Factor IRecombinant ProteinsStem Cell Factor

Identifiers

PMID7518834
PMCPMC296279
OpenAlexW2053889807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.